On the stock market since 2016, it operates in the world of health and science. It has 10,600 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 46% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $3.5B would still be left in the vault — a solid cushion for hard times.
The stock trades 54% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 56% a year on average.
There is $4.5B in the vault; even if every debt were paid off, $3.5B would remain.
The average analyst price target is $258 — 40% above today’s price.
The company’s market value is 70 times its annual profit. Even a small disappointment could hit the price hard.
Over the last 12 months, executives reported 189 sells against just 46 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, BGNE sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BGNE is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.